Pieris, Sanofi deal
The companies will expand a 2010 deal under which Pieris is using its Anticalin technology to discover and develop Anticalin candidates against undisclosed targets selected by Sanofi to include an additional multi-specific Anticalin program. For the new program, Pieris will receive an undisclosed upfront payment plus research funding and will be eligible for undisclosed milestones.
The 2010 deal initially included two single targets with an option to select four additional single targets. Pieris received €3.5 million ($4.6 million) up front for the first two targets, plus committed research funding. For each product developed under the 2010 deal, Pieris is eligible for up to €26.5 million ($34.7 million) in developmental milestones for the first therapeutic application and €18 million ($23.5 million) in commercial milestones, plus tiered royalties. ...